Barinib Tablet 4 mg contains Baricitinib, an oral medication belonging to the class of Janus kinase (JAK) inhibitors. It is primarily prescribed for the treatment of moderate to severe rheumatoid arthritis (RA) in adult patients who have not responded adequately to conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate.

Baricitinib works by modulating the immune system to reduce inflammation, pain, and joint damage caused by autoimmune activity. By targeting specific signaling pathways in the body, Barinib Tablet 4 mg helps improve joint function, reduce swelling, and enhance overall quality of life for patients living with chronic inflammatory conditions.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

How It Works

Baricitinib exerts its therapeutic effect through selective inhibition of Janus kinase (JAK) enzymes, which are critical in the signaling pathways of cytokines and growth factors involved in inflammation. The key mechanisms include:

• Suppressing Cytokine Signaling: Reduces excessive immune system activity that causes inflammation and joint damage.

• Decreasing Inflammation: Lowers the production of pro-inflammatory mediators responsible for pain, swelling, and stiffness.

• Slowing Disease Progression: Helps prevent joint erosion and functional disability over time.

By targeting the root inflammatory pathways, Barinib Tablet 4 mg offers effective control of symptoms and slows the progression of autoimmune joint disease.

Indications

Barinib Tablet 4 mg is indicated for:

• Moderate to severe rheumatoid arthritis: For adults who have shown an inadequate response to DMARDs such as methotrexate.

• Inflammatory autoimmune conditions: As prescribed by a healthcare provider in cases requiring immune modulation.

It is intended for adults and should be administered under the guidance of a rheumatologist or physician experienced in managing autoimmune disorders.

Dosage and Administration

• Recommended Dose: 4 mg orally once daily, with or without food.

• Swallow the tablet whole with water; do not crush, split, or chew.

• Consistency in daily dosing is important for maintaining optimal therapeutic effect.

• Dose adjustments may be required for patients with kidney impairment or other comorbid conditions, as advised by a physician.

• Regular monitoring is recommended, including blood counts and liver function tests, to ensure safety and effectiveness.

Benefits of Barinib Tablet

• Reduces pain, swelling, and stiffness associated with rheumatoid arthritis

• Improves joint mobility and functional ability

• Slows progression of joint damage and disability

• Convenient once-daily oral administration

• Provides a targeted therapy option for patients unresponsive to conventional DMARDs

Possible Side Effects

Barinib Tablet 4 mg is generally well tolerated, but side effects may occur, including:

• Upper respiratory tract infections

• Nausea or headache

• Increased risk of viral infections such as herpes zoster

• Changes in blood counts, liver enzymes, or cholesterol levels

• Rarely, serious infections or thromboembolic events

Patients should report any persistent fever, unusual fatigue, signs of infection, or unexpected bruising immediately.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Not recommended in patients with known hypersensitivity to Baricitinib.

• Use caution in patients with active infections or history of recurrent infections.

• Avoid live vaccines during treatment unless advised by a healthcare provider.

• Pregnant or breastfeeding women should only use under strict medical supervision.

• Inform your doctor about all concurrent medications to prevent potential interactions.

Storage Instructions

Store below 30°C in a dry, cool place, protected from light and moisture. Keep out of reach of children.

Barinib Tablet 4 mg (Baricitinib) is a safe and effective option for managing moderate to severe rheumatoid arthritis, controlling inflammation, and improving joint function when used under proper medical supervision.